Beowulf Mining, Indivior and RM2 International

“Blue-chips confounded forecasts and edged into positive territory at the start of December following on from a positive overnight session on Wall Street,” says AJ Bell Investment Director Russ Mould.

“Beowulf Mining’s shares plummeted after an administrative board in Sweden decided that it would not recommend the award of an exploitation concession for Kallak North to the government. This is a bitter pill for the company which has continued to invest on the basis that it had satisfied the requirements to be granted the concession. Beowulf’s shares were down by over 44.7% in early trading.

“Pharmaceutical group Indivior was a double-digit riser after its treatment for people addicted to opiods got approval from the US Food and Drug Administration. Indivior’s Sublocade has been approved for people who have started treatment with a transmucosal buprenorphine-containing product and have been on a stable dose of the treatment for at least seven days. The approval also makes it clear that Sublocade must be administered by healthcare providers and used as part of a complete treatment programme that includes counselling and psychosocial support. Indivior’s shares were up by more than 10.8% in early trading.

“Pallet provider RM2 International’s shares tumbled after it revealed it had not yet been able to secure sufficient funding to provide a production forecast for its Chinese manufacturing partner Zhenshi. RM2 had had stated in September that it intended to provide a 12-month production forecast by the end of November. RM2 has sufficient cash to continue operating through January and remains in takes with potential funding partners. RM2’s shares were down by 16%.”

These articles are for information purposes only and are not a personal recommendation or advice.